| Drug ID: | Drug99 |
|---|---|
| Drug Name: | Cefuroxime |
| CID: | 5479529 |
| DrugBank ID: | DB01112 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT00355602 |
| Molecular Formula: | C16H16N4O8S |
| Molecular Weight: | 424.4 g/mol |
| Isomeric SMILES: | CO/N=C(/C1=CC=CO1)\\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O |
| Synonyms: | cefuroxime; 55268-75-2; Cephuroxime; Cefuroxim; Cefuroximo; Cefuroximum; Sharox; Zinacef Danmark; Biofuroksym; Cefuril |
| Phase 0: | 3 |
| Phase 1: | 1 |
| Phase 2: | 7 |
| Phase 3: | 5 |
| Phase 4: | 34 |
| Description: | Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt841 | 5479529 | Cefuroxime | 847 | CAT | Rattus norvegicus (Norway rat) | 30797828 | Cefuroxime results in decreased activity of CAT protein |
| dt842 | 5479529 | Cefuroxime | 3119 | HLA-DQB1 | Homo sapiens (human) | 25811541 | Cefuroxime affects the expression of HLA-DQB1 mRNA |
| dt843 | 5479529 | Cefuroxime | 3133 | HLA-E | Homo sapiens (human) | 25811541 | Cefuroxime affects the expression of HLA-E mRNA |
| dt844 | 5479529 | Cefuroxime | 3586 | IL10 | Homo sapiens (human) | 16939481 | Cefuroxime inhibits the reaction [lipopolysaccharides results in increased secretion of IL10 protein] |
| dt845 | 5479529 | Cefuroxime | 4780 | NFE2L2 | Mus musculus (house mouse) | 30203046 | Cefuroxime results in decreased activity of NFE2L2 protein |
| dt846 | 5479529 | Cefuroxime | 9970 | NR1I3 | Mus musculus (house mouse) | 30203046 | Cefuroxime results in decreased activity of NR1I3 protein |
| dt847 | 5479529 | Cefuroxime | 5465 | PPARA | Mus musculus (house mouse) | 30203046 | Cefuroxime results in decreased activity of PPARA protein |
| dt848 | 5479529 | Cefuroxime | None | -- | Clostridium perfringens str. 13 | 7968655 | Inhibitor |
| dt849 | 5479529 | Cefuroxime | 6564 | SLC15A1 | Homo sapiens (human) | 15567297 | Inhibitor |
| dt850 | 5479529 | Cefuroxime | 6565 | SLC15A2 | Homo sapiens (human) | 15567297 | Inhibitor |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT00355602 | Antibiotics for the Treatment of Ulcerative Colitis | None | COMPLETED | University of Dundee | Colitis, Ulcerative | DRUG: Cefuroxime|DRUG: Ciprofloxacin|DRUG: Clarit… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
No related literature
You can run management commands to establish drug-literature associations